There are currently 580 clinical trials in Denver, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Porter Adventist Hospital, National Jewish Health, Rose Medical Center and Colorado Blood Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
NCT06015308
Recruiting
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis [Tdap]) and Pneumovax 23 (PPSV) vaccines in ad... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Velocity Clinical Research - Denver Site Number : 8401168, Denver, Colorado
Conditions: Dermatitis Atopic
Register for Updates
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651
Recruiting
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Rocky Mountain Cancer Centers - Aurora, Denver, Colorado
Conditions: Colorectal Neoplasms
Register for Updates
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
NCT05326412
Recruiting
This study is an exploratory, two-part, 12-week, Phase 2a study to evaluate the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years. This study consists of participants who have been on a standard-of-care (SoC) mono (long-acting β2-agonist [LABA]) or long-acting muscarinic antagonist [LAMA]), double (inhaled corticosteroid [ICS] + LABA, LABA + LAMA or ICS + LAMA), or triple (ICS + LABA + LAMA) cont... Read More
Gender:
All
Ages:
Between 40 years and 70 years
Trial Updated:
06/17/2024
Locations: ~National Jewish Health Site Number : 8400012, Denver, Colorado
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
NCT05398263
Recruiting
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/17/2024
Locations: Research Site, Denver, Colorado
Conditions: Asthma
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Denver, Colorado
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05536804
Recruiting
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Kidney Associates of Colorado, Denver, Colorado
Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Register for Updates
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR)... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
06/17/2024
Locations: University of Colorado Cancer Center, Denver, Colorado
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
NCT05482893
Recruiting
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PT886. Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, and pancreatic ductal adenocarcinoma (PDAC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Sarah Cannon Research Institute (SCRI), Denver, Colorado
Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT05890729
Recruiting
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/17/2024
Locations: Xentria Investigative Site, Denver, Colorado
Conditions: Pulmonary Sarcoidosis
Register for Updates
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835
Recruiting
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Z... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Denver Health Outpatient Medical Center, Denver, Colorado
Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Register for Updates
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
06/17/2024
Locations: Colorado Neurological Research Center, PC, Denver, Colorado
Conditions: Alzheimer Disease
Register for Updates
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
NCT06111586
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study that consists of 2 parts. In Part A the safety of the highest dose-level of frexalimab in adults (age range 18-35 y.o.) will be established. In Part B, a dose-finding study (adolescents and young adults, 12-21 y.o.) evaluating the safety and efficacy of 3 age-adjusted dose-levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. The purpose of this study is to determine safety a... Read More
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
06/17/2024
Locations: University of Colorado Site Number : 8400003, Denver, Colorado
Conditions: Type 1 Diabetes Mellitus
Register for Updates